We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
BioCryst Pharmaceuticals, Inc. announced that it has priced a registered direct
offering for the sale of 4,350,000 shares of its common stock at a price of
$5.50 per share to institutional investors.
Otsuka Pharmaceutical has announced that it has concluded a collaborative research
and licensing agreement with Galenea, a Massachusetts-based bioventure company,
as of Jan. 8.
Akorn, Inc. announced that it has entered into the agreement to license a patent
titled, "M-EDTA Pharmaceutical Preparations of Uses Thereof" (the
"Invention") and related technology rights invented by Issam I.
Ivax Corp. agreed to buy Phoenix Scientific, a generic veterinary drugmaker.
An agreement calls for Ivax to pay a combination of $196.85 million in cash
and $75 million common stock for all of Phoenix.
Entelos Inc., a Foster City-based biosimulation technology company, announced
that it will extend its partnership with international pharmaceutical company
Organon International to co-develop and commercialize biologic and small molecule
rheumatoid arthritis therapies.
Solvay Pharmaceuticals has signed an agreement with the Norwegian authorities
whereby Solvay Pharmaceuticals will supply influenza vaccines to Norway in the
case of a pandemic.
Elscint Ltd. announced that Teva Pharmaceutical Industries
Ltd. has exercised its option to enter into a joint venture with Gamida-Cell
Ltd., in which Elscint (through a wholly owned subsidiary) holds 29.2 percent
on a fully diluted basis, in order to develop and commercialize StemEx for the
treatment of Leukemia and Lymphoma.
The FDA has named John Gardner director of the Division of Compliance Risk Management
and Surveillance (DCRMS), which operates within the Center for Drug Evaluation
and Research's Office of Compliance.
Radio-frequency identification (RFID) use in the pharmaceutical industry is
growing under state and federal mandates to secure the supply chain and prevent
counterfeiting, but technology limitations and security weaknesses may slow
full implementation, according to an ABI Research study, "The RFID Life
Sciences Market," which looks at the driving forces behind adoption and
RFID's benefits.